FXYD2
ENSG00000137731
Target class
Ion channel
Chromosome
11
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Other names
- MGC12372
- Target name
- FXYD2
- Gene name
- FXYD domain containing ion transport regulator 2
- Gene symbol
- FXYD2
- Protein name
- Sodium/potassium-transporting ATPase subunit gamma (Na(+)/K(+) ATPase subunit gamma) (FXYD domain-containing ion transport regulator 2) (Sodium pump gamma chain)
- ATP1G1
- HOMG2
- Gene biotype
- Protein coding
- Gene family
- FXYD domain containing ion transport regulators
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 17
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 574.81
- Tissue specificity (Gini)
- 0.939
- Tissue specificity (tau)
- 0.987
- KEGG gene identifiers
- hsa:486
- Protein interaction confidence
- 0.893455
- Protein interaction partners
- 22
- R-HSA-5578775
- R-HSA-936837
- R-HSA-9679191
- End position
- 117828698
- Start position
- 117800839
- Chromosome
- 11
- Strand
- Reverse
- Membrane
- Single-pass type III membrane protein .
- Mitochondria
- Tissue specificity (tau)
- 0.987107
- Expression inequality (Gini)
- 0.938999
Expression in transcripts per million
- Kidney - Medulla
- 574.81
- Kidney - Cortex
- 299.04
- Pancreas
- 37.94
- Minor Salivary Gland
- 9.36
- Ovary
- 5.83
Expression in transcripts per million
- Kidney - Medulla574.81
- Kidney - Cortex299.04
- Pancreas37.94
- Minor Salivary Gland9.36
- Ovary5.83
- Cells - EBV-transformed lymphocytes3.92
- Uterus3.46
- Testis2.53
- Spleen2.29
- Fallopian Tube2.21
- Liver2.04
- Colon - Sigmoid1.78
- Pituitary1.21
- Cervix - Endocervix1.18
- Thyroid1.15
- Prostate1.11
- Esophagus - Gastroesophageal Junction1.04
- Brain - Cerebellum0.99
- Brain - Cerebellar Hemisphere0.98
- Vagina0.96
- Lung0.94
- Bladder0.92
- Cervix - Ectocervix0.89
- Esophagus - Muscularis0.83
- Small Intestine - Terminal Ileum0.78
And 29 more, listed on the interactive page.
- GO:0005886
- GO:0005890
- GO:0070062
Related records
Trials (335)
- 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
- A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
- A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)
- A Clinical Trial of Patients With Melanoma
- A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
- A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants
- A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
- A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants
- A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants
- A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects
- A Drug Interaction Study of ACH-0145228
- A Drug Interaction Study of Albiglutide and Digoxin
- A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
- A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
- A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin
- A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
- A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
Drugs (6)
- Acetyldigitoxin Sodium/potassium-transporting ATPase inhibitor
- Deslanoside Sodium/potassium-transporting ATPase inhibitor
- Digitoxin Sodium/potassium-transporting ATPase inhibitor
- Digoxin Sodium/potassium-transporting ATPase inhibitor
- Istaroxime Sodium/potassium-transporting ATPase inhibitor
- Lanatoside C Sodium/potassium-transporting ATPase inhibitor